Oscar Health, Inc.
30.99USD
-2.3300 (-6.99%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on OSCR.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.17▲ | -$0.2 | 4 | 0 |
| Next quarter | -$1.08▲ | -$1.23 | 5 | 0 |
| Current year | $1.94▲ | $1.06 | 5 | 0 |
| Next year | $2.22▲ | $1.49 | 6 | 0 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.38 | $1.1 | +0.72 (+189.2%) |
| 2026-03-31 | $1.1 | $2.07 | +0.97 (+88.2%) |
| 2025-12-31 | -$0.92 | -$1.24 | -0.32 (-34.6%) |
| 2025-09-30 | -$0.58 | -$0.53 | +0.05 (+8.7%) |
85 ratings from 14 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Neutral | $26 $36 | Oct 12, 2026 |
| Raymond James | Maintained | Outperform | $34 $42 | Sep 18, 2026 |
| B of A Securities | Maintained | Underperform | $28 $30 | Sep 17, 2026 |
| Stephens & Co. | Reiterated | Equal-Weight | $34 | Sep 17, 2026 |
| Barclays | Maintained | Overweight | $39 $49 | Sep 17, 2026 |
| Baird | Maintained | Neutral | $27 $33 | Sep 17, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $20 $27 | Aug 13, 2026 |
| UBS | Maintained | Neutral | $20 $26 | Aug 7, 2026 |
| Barclays | Maintained | Overweight | $35 $39 | Aug 7, 2026 |
| Barclays | Upgraded from Equal-Weight | Overweight | $30 $35 | Jun 10, 2026 |
| Barclays | Maintained | Equal-Weight | $21 $30 | May 26, 2026 |
| UBS | Maintained | Neutral | $15 $20 | May 7, 2026 |
| Barclays | Maintained | Equal-Weight | $18 $21 | May 7, 2026 |
| Baird | Maintained | Neutral | $15 $19 | May 7, 2026 |
| Wolfe Research | Initiated | Peer Perform | — | May 6, 2026 |
| Jefferies | Upgraded from Underperform | Hold | $10 $16 | Apr 20, 2026 |
| UBS | Upgraded from Sell | Neutral | $12 $17 | Jan 9, 2026 |
| Barclays | Upgraded from Underweight | Equal-Weight | $13 $18 | Jan 5, 2026 |
| Stephens & Co. | Initiated | Equal-Weight | $17 | Dec 11, 2025 |
| Piper Sandler | Upgraded from Neutral | Overweight | $13 $25 | Nov 26, 2025 |
| Wells Fargo | Maintained | Underweight | $14 $11 | Nov 13, 2025 |
| Barclays | Maintained | Underweight | $11 $13 | Nov 10, 2025 |
| UBS | Maintained | Sell | $11 $12 | Nov 7, 2025 |
| Goldman Sachs | Initiated | Neutral | $17 | Oct 14, 2025 |
| Wells Fargo | Maintained | Underweight | $10 $14 | Oct 7, 2025 |
100 filings from 21 insiders · 8 buy / 19 sell over 6m
Officers and directors of OSCR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gassen WilliamDirector | GrantDeferred Stock Unit | 698 | $33.10 | $23k | Oct 8, 2026 |
| Plouffe DavidDirector | GrantDeferred Stock Unit | 641 | $33.10 | $21k | Oct 8, 2026 |
| Sankaran SidDirector | GrantDeferred Stock Unit | 1.5k | $33.10 | $49k | Oct 8, 2026 |
| WITTMAN VANESSA AMESDirector | Sell | 25.0k | $32.24 | $806k | Sep 18, 2026 |
| BALTRUS VICTORIAOfficer | Sell | 958 | $31.45 | $30k | Sep 3, 2026 |
| BLACKLEY RICHARD SCOTTChief Financial Officer | Sell | 28.9k | $31.45 | $908k | Sep 3, 2026 |
| MCANANEY ADAMOfficer | Sell | 9.1k | $31.45 | $286k | Sep 3, 2026 |
| SCHLOSSER MARIO TDirector | Sell | 31.4k | $31.45 | $988k | Sep 3, 2026 |
| LIANG JANETOfficer | Sell | 10.4k | $31.45 | $326k | Sep 3, 2026 |
| SCHLOSSER MARIO TDirector | Other | 750.0k | — | — | Aug 28, 2026 |
| SCHLOSSER MARIO TDirector | Sell | 750.0k | $30.34 | $22.82M | Aug 28, 2026 |
| BLACKLEY RICHARD SCOTTChief Financial Officer | Sellindirect | 18.8k | $31.74 | $595k | Aug 18, 2026 |
| SCHLOSSER MARIO TDirector | Otherindirect | 47.5k | — | — | Jul 1, 2026 |
| SCHLOSSER MARIO TDirector | Sellindirect | 47.5k | $29.50 | $1.48M | Jul 1, 2026 |
| BERTOLINI MARK TChief Executive Officer | Sell | 1.24M | $28.35 | $35.77M | Jun 30, 2026 |
| BERTOLINI MARK TChief Executive Officer | Sell | 1.21M | $28.60 | $34.91M | Jun 26, 2026 |
| SCHLOSSER MARIO TDirector | Other | 1.03M | — | — | Jun 23, 2026 |
| SCHLOSSER MARIO TDirector | Sell | 1.03M | $28.95 | $30.18M | Jun 23, 2026 |
| WITTMAN VANESSA AMESDirector | Grant | 8.5k | — | — | Jun 4, 2026 |
| LANG LAURA WDirector | Grant | 8.5k | — | — | Jun 4, 2026 |
Analyst Ratings
10 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 0 | 7 | 0 | 1 | Hold2.64 |
| 1 mo ago | 3 | 0 | 7 | 0 | 1 | Hold2.64 |
| 2 mo ago | 3 | 0 | 7 | 0 | 1 | Hold2.64 |
| 3 mo ago | 3 | 0 | 7 | 0 | 1 | Hold2.64 |
Members whose judged calls on OSCR have played out most reliably.
No settled calls on OSCR yet. 1 call is open, the first due Oct 12, 2027.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice